A groundbreaking ceremony was held in Rahway, NJ for Merck’s new FLEx facility that incorporates G-CON’s prefabricated cleanroom units.
Merck (known as Merck, Sharp, and Dohme outside the United States and Canada) held the groundbreaking ceremony for its Formulation Laboratory, Experimental (FLEx) Center in Rahway, NJ, with its collaboration partners, including G-CON Manufacturing, the companies announced in a June 13, 2019 press release. In February 2019, Merck announced the selection of G-CON’s prefabricated, flexible cleanroom units (PODs) for the new FLEx Center based on the PODs’ flexibility, speed, and ability to be repurposed. The facility is designed to make manufacturing more agile and sustainable and will provide improved flexibility in pharmaceutical formulation and process development for both sterile and oral solid-dosage products. Construction has commenced, and the facility is scheduled to open in 2021.
“The groundbreaking of the FLEx center at our Rahway, NJ site commences our journey to establish a world-class pharmaceutical processing facility that is reconfigurable with the evolving and dynamic technology needs of our pipeline,” said Allen C. Templeton, vice-president, Pharmaceutical Sciences at Merck Research Laboratories, in the press release. “We are pleased to collaborate with G-CON, along with other key construction and equipment providers, to enable our vision to create more effective means to develop and manufacture our products.”
Source: G-CON, Merck
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.